4Kscore News

New York, NY – Prostate cancer is the second most common cancer among men, and it is estimated that nearly three million men are living with the disease in the United States. Thankfully, many prostate cancers can be caught early on and either successfully treated or diagnosed as indolent (non-aggressive).

Early detection of prostate cancer begins with screening the Prostate Specific Antigen (PSA) to assess the health of the prostate. All men should get a PSA test, and know their PSA number and what it means. If a PSA test result is high, often times a doctor may recommend a biopsy. However, because the PSA test cannot distinguish between aggressive prostate cancer and other less serious conditions, many men with a high PSA may be subjected to unnecessary prostate biopsies.

Posted by 4Kscore on Dec 8, 2016 12:00:00 PM

For Prostate Cancer Awareness Month, Hattiesburg American News spoke with our client Hattiesburg Clinic Urology about the 4Kscore, a revolutionary test that predicts a man’s risk of developing aggressive prostate cancer. The test assists physicians, urologists, and nurse practitioners in making better-informed patient care decisions. Please read the full article below and see the original post on Hattiesburg American News.

September is Prostate Cancer Awareness Month

“Approximately 1 in 7 men will be diagnosed with prostate cancer during his lifetime, according to the American Cancer Society. In 2016, specifically, the ACS estimates 180,890 new cases of prostate cancer will be diagnosed, with more than 26,000 of those resulting in death.

Posted by 4Kscore on Oct 4, 2016 12:00:00 PM

OPKO Health, Inc. (NYSE: OPK) today announced that senior management will discuss recent draft local coverage determinations by certain Medicare Administrative Contractors for OPKO’s 4Kscore® test at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 11:30 AM (EDT). OPKO previously announced that Novitas Solutions issued a positive draft local coverage determination proposing to establish reimbursement coverage for patients with PSA levels > 3 ng/mL who have not yet had a biopsy, or patients with a PSA level of > 3 ng/mL who have had at least one prior negative biopsy and are considered to be at higher risk. The draft coverage determination was subsequently retired by Novitas due to a potential conflict with another Medicare Administrative Contractor. Palmetto GBA had issued a draft non-coverage determination on May 27^th for the 4Kscore test.

Posted by 4Kscore on Jun 17, 2016 12:00:00 PM

OPKO Health, Inc. (NYSE:OPK) (“OPKO” or the “Company”) announces that Novitas Solutions has issued a draft local coverage determination for the 4Kscore^® Test, the only blood test that accurately identifies an individual patient’s risk for high-grade, aggressive prostate cancer. Novitas Solutions is a Medicare Administrative Contractor (MAC) for Medicare jurisdictions L and H, with responsibility for nearly 10 million Medicare beneficiaries in New Jersey, Pennsylvania, Maryland, the District of Columbia and Texas, among other geographies.

Posted by 4Kscore on May 27, 2016 12:00:00 PM

OPKO Health, Inc. (NYSE:OPK) today announced the decision of the European Association of Urology (EAU) Prostate Cancer Guidelines Panel to include the 4Kscore® Test in the 2016 EAU Guidelines for Prostate Cancer. The panel concluded that the 4Kscore, as a blood test with greater specificity over the PSA test, is indicated for use prior to a first prostate biopsy or after a negative biopsy to assist patients and physicians in further defining the probability of high-grade cancer.

Posted by 4Kscore on Mar 15, 2016 12:00:00 PM